Management and Monitoring of the Diabetic Cat
World Small Animal Veterinary Association World Congress Proceedings, 2014
Claudia Reusch, DECVIM-CA
Clinic for Small Animal Internal Medicine, Zürich, Switzerland

The primary goal of treatment is to eliminate the clinical signs of diabetes (e.g., polyuria, polydipsia, polyphagia, weight loss), to prevent complications (e.g., hypoglycaemia, DKA), and to increase the chance of diabetic remission. Another goal is to minimize the potential negative impact of the cat's disease on the owner and thereby avoid cessation of therapy or euthanasia. The factors with the most negative impact on quality of life are boarding difficulties, owners wanting more control on diabetes, difficulties leaving cat with friends or family, general worry about diabetes, worry about hypoglycaemia, adapting social life, diabetes-related costs, and adapting work life. The veterinarian should make amendments to the protocol accordingly (e.g., simplification of treatment if social life, work life or costs are the major problems; access to home monitoring of blood glucose (HM) if owner wants more control; and avoidance of tight glucose regulation if owner is worried about hypoglycaemia).

After diagnosing the disease (by means of appropriate clinical signs, hyperglycemia, increased fructosamine), further workup should clarify the severity of diabetes and the presence of concurrent disease (e.g., urinary tract infection, stomatitis, pancreatitis). Insulin is the mainstay of treatment in diabetic cats. Currently available non-insulin antidiabetic medications have either a rather low success rate, are not suitable as monotherapy, or have not yet been adequately evaluated in diabetic cats. Feeding a low-carbohydrate high-protein diet is considered to be advantageous and may increase remission rates. Some cats, however, refuse eating a particular diet, often times adequate glycemic control may still be achieved by feeding the usual food. In the vast majority of diabetic cats, dietary measures alone are insufficient to get control over the disease. Treatment should be initiated immediately and generally include twice-daily insulin application (e.g., Lantus®, ProZinc®, Caninsulin®) and high-protein low-carbohydrate diet. At our institution, we start with an initial insulin dose of 1 U/cat BID in cats weighing ≤ 4 kg and 1.5–2.0 U/cat BID in cats weighing > 4 kg. In cats with a blood glucose concentration < 20 mmol/l at the time of diagnosis, no more than 1 U/cat BID is given, independent of the body weight. Diabetogenic drugs (glucocorticoids, progestagens) should be ceased whenever possible. Initially, frequent reevaluations are mandatory to titrate the insulin dose, to avoid oversight of diabetic remission, and to identify cats with difficult-to-regulate diabetes requiring further workup. Reevaluations should be scheduled as a minimum after 1, 2–3, 6–8, 10–12, 14–16 weeks after initiating treatment; thereafter, the frequency can be reduced to approximately every 4 months. Measures taken at each reevaluation include review of the daily log of the owner (including results of HM), evaluation of body weight, physical examination, measurement of serum fructosamine, and generation of a blood glucose curve (BGC). To minimize the influence of lack of food intake on the result of the BGC, the owner should give insulin and food at home, and then bring the cat to the hospital as soon as possible (within 2 hours). Thereafter, glucose is measured every 2 hours (or every 1 hour if hypoglycaemia is suspected) for at least 10 hours. In-hospital BGCs are prone to be affected by stress and consequently, blood glucose concentrations may rise continuously throughout the day or glucose levels may be high from the beginning. Lack of food intake in cats used to eat frequent meals has the opposite effect as it may result in low blood glucose concentrations. In-hospital BGCs should therefore be interpreted with great caution. In cats in which owners perform HM on a regular basis, generation of in-hospital BGCs can be omitted. Fructosamine concentrations roughly reflect the quality of glycemic control of the previous 1 to 2 weeks. The parameter is neither affected by short-term increase in blood glucose concentration (e.g., stress hyperglycemia) nor by lack of food intake. Reference ranges of fructosamine differ to some degree between laboratories. If a normal fructosamine is found, careful evaluation of the cat (including BGCs, best generated at home) should be done to check for hypoglycemia and/or diabetic remission. If fructosamine is high (e.g., > 550 µmol/l), the various possible reasons for poor regulation have to be considered (e.g., application error, insulin underdose, too short duration of insulin effect, Somogyi phenomenon, concurrent diseases causing insulin resistance). The parameter is less important than the evaluation of clinical signs and body weight and generation of BGCs. Measurement of fructosamine is helpful to get an overall impression on the quality of glycaemic control, to clarify the effect of stress on blood glucose concentrations and to clarify discrepancies between the history, physical examination findings, and BGCs. Monitoring at home is as important (resp. even more important) than monitoring in the hospital. The owner should log well-being, water and food intake, insulin dose daily, and body weight once per week. Home monitoring is strongly encouraged as it provides more reliable information than blood glucose measured in the hospital. The majority of owners are able to learn to do HM and appreciate to have more control over the disease. Home monitoring is particularly helpful to identify hypoglycaemia, which occurs quite frequently in cats experiencing diabetic remission. Owners should be introduced to HM as fast as possible after initiating therapy (e.g., during the first or second reevaluation). Teaching capillary blood sampling with a lancing device and the use of a portable glucose meter (PBGM) should take at least 30 minutes and should be done by an experienced technician or veterinarian. Capillary blood may be obtained from various sites, such as pinna, metacarpal and metatarsal pads interchangeably. Only PBGM for which independent quality control studies have been performed should be used. To generate a BGC, the glucose concentration before the morning insulin injection should be measured and every 2 hours thereafter until the evening insulin injection is due. Hourly measurements should be suggested if hypoglycaemia is suspected. Many owners need additional support (e.g., by telephone) during the initial phase of performing HM and it is important that veterinary help is readily available. During the first 3–4 months of therapy, a BGC should be generated approximately every 5 to 7 days. After stabilisation (and if no remission is achieved), the time intervals can be prolonged to every 3–4 weeks. Additionally, the fasting blood glucose should be measured twice weekly and a spot glucose check performed whenever the owner feels uncertain about the well-being of the cat. It has to be considered that HM may pose an additional burden on the owner and the veterinarian needs to evaluate carefully if and when an owner is prepared for the procedure. Owners who are unable to perform HM may use urine glucose measurements in all urine samples voided throughout one day per week. Results should only be used as a rough estimate and insulin dose should not be amended based on urine glucose measurements. Persistent glycosuria suggests inadequate control; lack of glucose can be due to excellent glycaemic control, diabetic remission or insulin overdose. Cats in which clinical signs have resolved and body weight is stable are usually well controlled, whereas persistence of clinical signs and unwanted weight loss are suggestive of poor glycemic control or the presence of another disease. BGCs are essential for the fine-tuning of insulin dose, to detect hypoglycemia (as cats often do not show clinical signs until blood glucose is extremely low), to tailor the insulin dose in case of diabetic remission, and to identify the exact problem in case of poor glycemic control. During the first 3–4 months of therapy, the interpretation of BGCs and treatment decision should be made by the veterinarian. During long-term management, many owners gain sufficient experience to make (slight) dose adjustments on their own according to written guidelines. See presentation "Which insulin in cats?" for more details on insulin preparations and dose adjustment.

References

1.  Kley S, Casella M, Reusch CE. Evaluation of long-term home monitoring of blood glucose concentrations in cats with diabetes mellitus: 26 cases (1999–2002). J Am Vet Med Assoc. 2004;225:261–266.

2.  Niessen SJ, Powney S, Guitian J, Niessen AP, Pion PD, Shaw JA, Church DB. Evaluation of a quality-of-life tool for cats with diabetes mellitus. J Vet Intern Med. 2010;24:1098–1105.

3.  Reusch CE, Kley S, Casella M. Home monitoring of the diabetic cat. J Feline Med Surg. 2006;8:119–127.

4.  Wess G, Reusch C. Capillary blood sampling from the ear of dogs and cats and use of portable meters to measure glucose concentration. J Small Anim Pract. 2000;41:60–66.

5.  Zeugswetter FK, Rebuzzi L, Karlovits S. Alternative sampling site for blood glucose testing in cats: giving the ears a rest. J Feline Med Surg. 2010;12:710–713.

  

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Claudia Reusch, DECVIM-CA
Clinic for Small Animal Internal Medicine
Zürich, Switzerland


MAIN : Feline Endocrinology : Monitoring Diabetic Cat
Powered By VIN

Friendly Reminder to Our Colleagues: Use of VIN content is limited to personal reference by VIN members. No portion of any VIN content may be copied or distributed without the expressed written permission of VIN.

Clinicians are reminded that you are ultimately responsible for the care of your patients. Any content that concerns treatment of your cases should be deemed recommendations by colleagues for you to consider in your case management decisions. Dosages should be confirmed prior to dispensing medications unfamiliar to you. To better understand the origins and logic behind these policies, and to discuss them with your colleagues, click here.

Images posted by VIN community members and displayed via VIN should not be considered of diagnostic quality and the ultimate interpretation of the images lies with the attending clinician. Suggestions, discussions and interpretation related to posted images are only that -- suggestions and recommendations which may be based upon less than diagnostic quality information.

CONTACT US

777 W. Covell Blvd., Davis, CA 95616

mailto:vingram@vin.com

PHONE

  • Toll Free: 800-700-4636
  • From UK: 01-45-222-6154
  • From anywhere: (1)-530-756-4881
  • From Australia: 02-6145-2357
SAID=27